研究業績

学会発表

術前薬物療法概論


黒井克昌* 、戸井雅和、大野真司、中村清吾、岩田広治、増田 慎三、佐藤信昭、津田 均、黒住昌史、秋山 太


第22回 日本乳癌学会 2014 シンポジウム1

Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer


Hiroji Iwata, Naohito Yamamoto, Norikazu Masuda, Hiroko Bando, Katsumasa Kuroi, Shinji Ohno, Hiroi Kasai, Satoshi Morita, Takaki Sakurai, Masakazu Toi


St.Gallen Poster

Cohort study evaluating trastuzumab in HER2 positive early breast cancer in Japan; JBCRG-C01


N. Masuda, H. Yamashiro, H. Iwata, R. Nishimura, N. Sato, T. Kamio, T. Saito, T. Lee, S. Yasuno, M. Toi


St Gallen 2013, 3

Safety of trastuzumab in HER2 positive primary breast cancer in Japan; Initial safety report for the large scale cohort study (JBCRG-C01)


N. Yamamoto, H. Yamashiro, H. Iwata, N. Masuda, S. ohtani, M. Takahashi, K. Yamazaki, M. Kato, S. Ohno, K. Kuroi, K. Yamagami, T. Morimoto, Y. Hasegawa, T. Takano, H. Shigematsu, M. Hosoda, H. Abe, S. Morita, S. Yasuno, M. Toi


2013 ASCO Poster

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (JBCRG-13)


Kenji Higaki, Norikazu Masuda, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani,Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi


2013 ASCO Poster

Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study)


Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katsumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yasuhiro Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita, Masakazu Toi


2013 SABCS Poster

A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC, and TC-FEC as preoperative chemotherapy for hormone receptor-positive and HER2-negative primary breast cancer: Japan Breast Cancer Research Group (JBCRG) – 09


Nobuaki Sato, Norikazu Masuda, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka, and Masakazu Toi


2013 SABCS Poster

JBCRG10年のあゆみと展望


黒井克昌


広島大学医学部 広仁会館2階 大会議室

Inter-observer concordance of Ki-67 labeling index inbreast cancer[br]: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study


T Ueno, Y Mikami, K Yoshimura, H Tsuda, M Kurosumi, S Masuda, R Horii, M Toi, and H Sasano


2012 SABCS Poster Session 5

A Prospective Multicenter Randomized Phase II Neo-Adjuvant Study of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Docetaxel, Cyclophosphamide and Trastuzumab (TCH) Versus TCH Followed by FEC Versus TCH Alone, in Patients (pts) with Operable HER2 Positive Breast Cancer: JBCRG-10 Study


Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M


2012 SABCS Poster Session 1

前のページへ 次のページへ
任意団体JBCRG 研究業績